McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion including debt. This acquisition expands McKesson's healthcare operations by adding home-based infusion treatment services, enhancing its portfolio beyond medicine and medical supply distribution. McKesson's shares rose 1.46% on the news, reflecting investor optimism about the strategic move.
McKesson's market cap stands at $106.73 billion as of Oct 06, 2026 21:36 WIB, with a dividend yield of 0.41%. On Pluang, the stock price is $918.70, showing a modest 0.36% gain in the last day. Trading volume is 697,614 shares, and typical hold time is 74 days, indicating steady investor interest despite a 61% sell order activity. This data provides a snapshot of McKesson's current market position alongside the recent acquisition news.
McKesson Corp and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health for about $5.8 billion, paying $32.05 per share, a 37% premium. CD&R will own 51% and McKesson 49% with McKesson investing $1.4 billion for its ...
The U.S. Supreme Court is considering whether a climate change lawsuit by Boulder County against Exxon and Suncor can proceed in state court, with potential nationwide impact. Meanwhile, Mattel faces activist investor pressure to explore strategic op...
